 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1993 | Volume 118 Issue 3 | Pages 195-198
Objective: To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia.
Design: Uncontrolled phase II trial.
Setting: Tertiary, referral cancer center.
Patients: Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated.
Intervention: 2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment.
Measurements and Main Results: A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed.
Conclusion: 2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.
Author and Article Information
From the University of Texas M. D. Anderson Cancer Center, Houston, Texas.
ARTICLE
Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine
Requests for Reprints: Meletios A. Dimopoulos, MD, University of Texas M. D. Anderson Cancer Center, Box 1, 1515 Holcombe Boulevard, Houston, TX 77030.
Acknowledgments: The authors thank Dean Anthony and Rose Guevara for preparing and editing this manuscript.
Grant Support: In part by the Hompe Myeloma Research Fund.
This article has been cited by other articles:
|
|
 |
|
  V. Leblond, V. Levy, F. Maloisel, B. Cazin, J.-P. Fermand, J.-L. Harousseau, L. Remenieras, R. Porcher, M. Gardembas, G. Marit, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease Blood, November 1, 2001; 98(9): 2640 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Morel, M. Monconduit, D. Jacomy, P. Lenain, B. Grosbois, C. Bateli, T. Facon, I. Dervite, F. Bauters, A. Najman, et al. Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients Blood, August 1, 2000; 96(3): 852 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Gertz, R. Fonseca, and S. V. Rajkumar Waldenstrom's Macroglobulinemia Oncologist, February 1, 2000; 5(1): 63 - 67. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Dimopoulos, P. Panayiotidis, L. A. Moulopoulos, P. Sfikakis, and M. Dalakas Waldenstrom’s Macroglobulinemia: Clinical Features, Complications, and Management J. Clin. Oncol., January 5, 2000; 18(1): 214 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K Morris, J. M Kolesar, and J. G Kuhn Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 94 - 109. [PDF]
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders Oncologist, June 1, 1996; 1(3): 125 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Gruber, F Geisen, R Sgonc, A Egle, A Villunger, G Boeck, G Konwalinka, and R Greil 2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA) Stem Cells, May 1, 1996; 14(3): 351 - 362. [Abstract]
|
|
Article
